Galactomannan C
Alternative Names: Carbohydrate polymer; DAVANAT®; GM-CT-01Latest Information Update: 13 Nov 2021
At a glance
- Originator Pro-Pharmaceuticals
- Developer Galectin Therapeutics; Icahn School of Medicine at Mount Sinai; Pro-Pharmaceuticals
- Class Antineoplastics; Mannans; Polymers
- Mechanism of Action Galectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Colorectal cancer
Highest Development Phases
- Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Hepatic fibrosis; Malignant melanoma
Most Recent Events
- 22 Mar 2019 Discontinued - Phase-I/II for Malignant melanoma (Combination therapy, Metastatic disease) in Belgium (IV)
- 12 Mar 2019 Cliniques universitaires Saint-Luc- Université Catholique de Louvain terminates a phase I/II trial in Malignant melanoma (Combination therapy, Metastatic disease) in Belgium (NCT01723813)
- 10 Aug 2017 Discontinued - Phase-II for Biliary cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV)